Published in Korean J Ophthalmol on January 21, 2014
The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol (2006) 25.47
The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol (2002) 16.89
Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol (2002) 14.17
Age-specific prevalence and causes of blindness and visual impairment in an older population: the Rotterdam Study. Arch Ophthalmol (1998) 4.91
A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol (2003) 4.52
A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol (2003) 4.35
The uniocular drug trial and second-eye response to glaucoma medications. Ophthalmology (2004) 3.10
Variation of 24-hour intraocular pressure in healthy individuals: right eye versus left eye. Ophthalmology (2005) 2.72
Twenty-four-hour intraocular pressure pattern associated with early glaucomatous changes. Invest Ophthalmol Vis Sci (2003) 1.97
Predicting response to glaucoma therapy in one eye based on response in the fellow eye: the monocular trial. Arch Ophthalmol (2008) 1.66
Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? Ophthalmology (2005) 1.61
The one-eye trial and fellow eye response to prostaglandin analogues. Clin Experiment Ophthalmol (2008) 1.61
Latanoprost and timolol combination therapy vs monotherapy: one-year randomized trial. Arch Ophthalmol (2002) 1.54
Pharmacological characterization of a novel antiglaucoma agent, Bimatoprost (AGN 192024). J Pharmacol Exp Ther (2003) 1.42
Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug. Exp Eye Res (2004) 1.35
A comparison of the fixed combination of latanoprost and timolol with its individual components. Graefes Arch Clin Exp Ophthalmol (2002) 1.32
A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertension. Br J Ophthalmol (2004) 1.30
Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J Ocul Pharmacol Ther (2003) 1.30
Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure. Ophthalmology (2004) 1.29
Patterns of care for open-angle glaucoma in managed care. Arch Ophthalmol (2003) 1.28
Bimatoprost/timolol fixed combination: a 3-month double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension. J Glaucoma (2008) 1.26
Asymmetry of right versus left intraocular pressures over 24 hours in glaucoma patients. Ophthalmology (2006) 1.20
Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Ophthalmology (2006) 1.13
Contralateral effect of topical beta-adrenergic antagonists in initial one-eyed trials in the ocular hypertension treatment study. Am J Ophthalmol (2000) 1.06
Conjunctival hyperemia and the use of topical prostaglandins in glaucoma and ocular hypertension. J Ocul Pharmacol Ther (2003) 1.05
The safety and efficacy of bimatoprost/timolol fixed combination: a 1-year double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension. J Glaucoma (2010) 1.04
Bimatoprost: mechanism of ocular surface hyperemia associated with topical therapy. Cardiovasc Drug Rev (2005) 1.02
Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients. Ophthalmology (2005) 1.01
Diurnal variation of intraocular pressure in suspected glaucoma patients and their outcome. Graefes Arch Clin Exp Ophthalmol (2007) 0.99
Discrepancy of the intraocular pressure response between fellow eyes in one-eye trials versus bilateral treatment: verification with normal subjects. J Glaucoma (2008) 0.97
Bimatoprost/timolol fixed combination vs latanoprost/timolol fixed combination in open-angle glaucoma patients. Eye (Lond) (2008) 0.94
24-Hour control with a latanoprost-timolol fixed combination vs timolol alone. Arch Ophthalmol (2006) 0.94
Twenty-four-hour control with latanoprost-timolol-fixed combination therapy vs latanoprost therapy. Arch Ophthalmol (2005) 0.91
The uniocular therapeutic trial in the management of elevated intraocular pressure. Surv Ophthalmol (1981) 0.90
Comparison of two fixed combinations of latanoprost and timolol in open-angle glaucoma. Graefes Arch Clin Exp Ophthalmol (1998) 0.90
A comparison of the safety and intraocular pressure lowering of bimatoprost/timolol fixed combination versus latanoprost/timolol fixed combination in patients with open-angle glaucoma. Curr Med Res Opin (2007) 0.86
Emerging perspectives in glaucoma: optimizing 24-hour control of intraocular pressure. Am J Ophthalmol (2002) 0.85
Diurnal variation of intraocular pressure in suspected normal-tension glaucoma. Jpn J Ophthalmol (2006) 0.84
Effects of brimonidine 0.2%-timolol 0.5% fixed-combination therapy for glaucoma. Jpn J Ophthalmol (2010) 0.83
The effect on diurnal intraocular pressure of the fixed combination of latanoprost 0.005% and timolol 0.5% in patients with ocular hypertension. Acta Ophthalmol Scand (2001) 0.83
The monocular trial controversy: a critical review. Curr Opin Ophthalmol (2009) 0.82
Effect on intraocular pressure during 24 hours after repeated administration of the fixed combination of latanoprost 0.005% and timolol 0.5% in patients with ocular hypertension. J Glaucoma (2001) 0.82
Latanoprost ophthalmic solution in the treatment of open angle glaucoma or raised intraocular pressure: a review. Clin Ophthalmol (2008) 0.82
Short-term effects of latanoprost on anterior chamber depth in patients with glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci (2006) 0.78
Long-term effects of prostaglandin analogues on the anterior chamber depth of patients with primary open-angle glaucoma. Cutan Ocul Toxicol (2009) 0.76
The efficacy of a monocular drug trial in normal-tension glaucoma. Korean J Ophthalmol (2012) 0.76
Ginkgo biloba extract and bilberry anthocyanins improve visual function in patients with normal tension glaucoma. J Med Food (2012) 0.87
Comparison of clinical characteristics between Korean and Western normal-tension glaucoma patients. Am J Ophthalmol (2013) 0.80
Effects of brimonidine timolol fixed combination therapy on anterior ocular segment configuration. Jpn J Ophthalmol (2011) 0.79
Increased expression of oxyproteins in the optic nerve head of an in vivo model of optic nerve ischemia. BMC Ophthalmol (2012) 0.77
Brimonidine 0.2% versus brimonidine Purite 0.15% in Asian ocular hypertension. J Ocul Pharmacol Ther (2007) 0.76
Associations between Optic Cup-to-disc Ratio and Systemic Factors in the Healthy Korean Population. Korean J Ophthalmol (2015) 0.75
Long-term Reliability of Diurnal Intraocular Pressure Patterns in Healthy Asians. Korean J Ophthalmol (2017) 0.75
The Relationship between Vitamin D and Glaucoma: A Kangbuk Samsung Health Study. Korean J Ophthalmol (2016) 0.75
Point-wise relationships between visual field sensitivity and macular thickness determined by spectral-domain optical coherence tomography. Curr Eye Res (2013) 0.75
Association between Renal Function and Open-Angle Glaucoma: The Korea National Health and Nutrition Examination Survey 2010-2011. Ophthalmology (2016) 0.75